Karayalcin B, Aras G, Erbay G, Ercan M T
Department of Nuclear Medicine, Ankara University Medical School, Turkey.
Nucl Med Commun. 1988 Sep;9(9):657-62. doi: 10.1097/00006231-198809000-00008.
99Tcm-dextran was evaluated as a lymphoscintigraphic agent in 10 normal volunteers and 24 patients with breast cancer. 99Tcm-dextran (0.5-1 mCi) in a volume of 0.1-0.2 ml was injected into the posterior rectus sheath in the subcostal site on one side. Scintigrams were obtained at 2-2.5 h after injection and the injection was repeated on the other side. The final image was taken at 4.5-5 h after the first injection. The normal distribution of lymph nodes and anatomical variations in scintigraphic images were first determined in normal subjects. In the patient group, eight scintigrams were evaluated as pathological and the rest as normal. In the 25 women whose lymphoscintigrams were normal the mean number of parasternal nodes visualized was six (range: 3-11). Bilateral symmetrical or asymmetrical chain was observed in 20 subjects (80%) and unilateral chain in five subjects (20%). There was cross-drainage in five subjects (20%). Supraclavicular lymph nodes were visualized in 11 subjects (44%). Varying abnormal images were obtained in eight patients. Our results are in good agreement with those reported in the literature, using radiocolloids. It is concluded that 99Tcm-dextran is a promising agent and may well replace radiocolloids because of the simplicity of the labelling procedure, stability of the label, easy availability and low cost.
对99锝-葡聚糖作为一种淋巴闪烁造影剂在10名正常志愿者和24例乳腺癌患者中进行了评估。将0.1 - 0.2毫升体积的99锝-葡聚糖（0.5 - 1毫居里）注入一侧肋下部位的腹直肌后鞘。在注射后2 - 2.5小时获取闪烁图像，然后在另一侧重复注射。在首次注射后4.5 - 5小时拍摄最终图像。首先在正常受试者中确定闪烁图像中淋巴结的正常分布和解剖变异。在患者组中，8幅闪烁图像被评估为病理性的，其余为正常。在25名淋巴闪烁造影正常的女性中，可视化的胸骨旁淋巴结平均数量为6个（范围：3 - 11个）。20名受试者（80%）观察到双侧对称或不对称链，5名受试者（20%）观察到单侧链。5名受试者（20%）存在交叉引流。11名受试者（44%）可见锁骨上淋巴结。8名患者获得了不同的异常图像。我们的结果与文献中使用放射性胶体报道的结果高度一致。结论是，99锝-葡聚糖是一种有前景的试剂，由于标记程序简单、标记稳定性好、易于获取且成本低，很可能会取代放射性胶体。
